Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Alpharadin (radium-223) in symptomatic hormone-refractory prostate cancer with bone metastases
2007-006195-11Phase 3Completed
- Sponsor
- Algeta ASA
- Start
- Feb 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Best standard of care + Alpharadin with Best standard of care + placebo (2 arms). Primary endpoint: Overall survival. Started Feb 2008; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2007-006195-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006195-11.